The Complete Neurotoxin Comparison Guide: Botox vs. Dysport vs. Xeomin vs. Daxxify vs. Letybo

While 'Botox' has entered the cultural lexicon as a generic term for wrinkle-relaxing injections, modern medical spas offer five distinct FDA-approved botulinum toxin type A pharmaceuticals: Botox Cosmetic (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Daxxify (daxibotulinumtoxinA-lanm), and Letybo (letibotulinumtoxinA-wlbg).

Each product shares the identical underlying therapeutic mechanism of action: cleaving the SNAP-25 intracellular protein within cholinergic presynaptic nerve terminals, inhibiting the vesicular exocytosis of acetylcholine, and temporarily relaxing targeted facial muscles.

However, they differ significantly in molecular weight, accessory protein coatings, diffusion halos, cellular stabilization, onset speed, and clinical duration. Understanding these pharmacological differences allows patients and providers to select the ideal neuromodulator for specific facial vectors.

One of the most frequent points of patient confusion is dosage comparison across brands. In the United States, botulinum toxin units are not standardized across manufacturers; a 'unit' represents an assay-specific biological activity measure (the median lethal dose, or LD50, in a murine model) determined by each pharmaceutical maker's proprietary laboratory testing.

The Same Labeled Dose (Botox, Xeomin, Letybo): All three labels specify the same glabellar dose, a total of 20 Units given as 4 Units into each of five sites. That is a matching labeled dose rather than a demonstrated equivalence. Every one of these labels states that its potency Units are specific to its own preparation and assay method and are not interchangeable with other botulinum toxin products.

The Dysport Number (50 Units, Not 20): The Dysport label specifies a total glabellar dose of 50 Units, given as five equal aliquots of 10 Units, where the Botox label specifies 20 Units across the same five sites. That labeled difference is where the ratio patients hear about comes from. Someone quoted 50 units of Dysport is not receiving more than double the medication; they are receiving that product's own labeled dose, which its label says cannot be converted to another brand's units.

Daxxify Dosing: The Daxxify label specifies a total glabellar dose of 40 Units, given as 8 Units into each of five sites, twice the labeled Botox dose across the same five sites. The Daxxify label states no duration of effect.

Why does a neurotoxin stop working for some long-term patients? The answer often lies in molecular structure and immune response.

Complexed Toxins (Botox, Dysport, Letybo): The active 150 kDa neurotoxin core is surrounded by accessory hemagglutinin and non-hemagglutinin non-toxic proteins, yielding a 900 kDa molecular complex. While these protective proteins historically shielded the toxin during manufacturing, your immune system can recognize them as foreign antigens, occasionally developing neutralizing antibodies that render future treatments ineffective ('toxin resistance').

The 'Naked' Neurotoxin (Xeomin): Merz Pharmaceuticals utilizes an additional chromatographic purification step that strips away all accessory complexing proteins. The Xeomin label describes the result as the active neurotoxin with a molecular weight of 150 kDa, without accessory proteins. None of these labels states a comparative rate of neutralizing antibody formation across brands, so any ranking of the products on that point is clinical opinion rather than a labeled claim.

Peptide Stabilization (Daxxify): Revance Therapeutics replaces human and animal donor proteins with a synthetic 35-amino-acid peptide excipient (RTP004). The Daxxify label describes that peptide as preventing surface adsorption and promoting thermal stability of the product. The label makes no duration claim for it.

When an injector administers neurotoxin, the solution diffuses in a microscopic radius (or 'halo') around the needle entry point before binding to motor endplates.

Broad Diffusion (Dysport): Dysport exhibits a wider, more feathery diffusion radius. This makes Dysport exceptionally effective for broad, hyperdynamic forehead musculature (the frontalis) and expansive neck platysmal bands, creating an airbrushed, natural softening without frozen patchiness. However, injectors must exercise extreme caution when treating near the orbital rim to avoid eyelid ptosis.

Tight, Localized Diffusion (Botox, Xeomin, Letybo, Daxxify): These agents remain tightly focused at the injection vector. They are the clinical instruments of choice for hyper-precise micro-tox indications: crow's feet near the lateral canthus, gummy smile reduction (LLSAN muscle), bunny lines along the nasal bones, depressor anguli oris (DAO) downturned mouth corners, and upper lip flip injections.

Patients planning treatments ahead of weddings, photoshoots, or public speaking engagements must carefully align product onset timelines with their event dates:

Onset Stated on a Label (Botox and Xeomin only): The Botox Cosmetic label states that the injected muscles are chemically denervated one to two days after injection, increasing in intensity during the first week. The Xeomin label states that the median onset of treatment effect occurs within two to seven days. The Dysport, Daxxify and Letybo labels state no onset for glabellar lines, so a faster onset quoted for those products is practice experience rather than a label statement.

Onset Reported in a Trial (Daxxify): In the SAKURA 1 and SAKURA 2 phase 3 studies, the median time to a clinically meaningful response was 3 days in each study. That is a trial median under a fixed dose, not a label statement. No label names a day on which a result should be judged, so a two week follow up is a practice convention rather than a regulated interval.

Duration Stated on a Label: Botox Cosmetic states that the duration of effect for glabellar lines is approximately 3 to 4 months. Dysport states that the clinical effect may last up to four months. Xeomin states that the typical duration of effect of each treatment is up to 12 to 16 weeks and that it may vary in individual patients. The Letybo label states no duration of effect at all.

Daxxify, and Where Its Numbers Come From: The Daxxify label states no duration of effect. The longer figures quoted at consultations come from the SAKURA 1 and SAKURA 2 phase 3 trials, which reported that glabellar line severity of none or mild was maintained for a median of 24.0 weeks in SAKURA 1 and 23.9 weeks in SAKURA 2, and that severity did not return to baseline for a median of 27.7 and 26.0 weeks. Follow up in those studies ran to a maximum of 36 weeks, so they report nothing about any point beyond that.